

# Ravindra Ganesh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5687004/publications.pdf>

Version: 2024-02-01

43  
papers

925  
citations

430874

18  
h-index

526287

27  
g-index

48  
all docs

48  
docs citations

48  
times ranked

737  
citing authors

#	ARTICLE	IF	CITATIONS
1	Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities. <i>Journal of Infectious Diseases</i> , 2022, 225, 598-602.	4.0	40
2	Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19. <i>Mayo Clinic Proceedings</i> , 2022, 97, 26-30.	3.0	22
3	Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	20
4	Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant. <i>Mayo Clinic Proceedings</i> , 2022, 97, 327-332.	3.0	17
5	The Female-Predominant Persistent Immune Dysregulation of the Post-COVID Syndrome. <i>Mayo Clinic Proceedings</i> , 2022, 97, 454-464.	3.0	52
6	Virtual Reality for Health Care Professionals During a Pandemic: A Pilot Program. <i>Journal of Primary Care and Community Health</i> , 2022, 13, 215013192210867.	2.1	2
7	Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. <i>Mayo Clinic Proceedings</i> , 2022, 97, 943-950.	3.0	4
8	Post-COVID-19 syndrome: persistent neuroimaging changes and symptoms 9 months after initial infection. <i>BMJ Case Reports</i> , 2022, 15, e248448.	0.5	3
9	Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	8
10	Postacute Sequelae of SARS-CoV-2 Infection—Lessons Learned From a Coordinated Health System Response. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2022, 6, 311-319.	2.4	4
11	Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019. <i>Journal of Patient Experience</i> , 2022, 9, 237437352211056.	0.9	1
12	Central Sensitization Phenotypes in Post Acute Sequelae of SARS-CoV-2 Infection (PASC): Defining the Post COVID Syndrome. <i>Journal of Primary Care and Community Health</i> , 2021, 12, 215013272110308.	2.1	28
13	Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19. <i>Journal of Primary Care and Community Health</i> , 2021, 12, 215013272110192.	2.1	40
14	Obesity Management Education Needs Among General Internists: A Survey. <i>Journal of Primary Care and Community Health</i> , 2021, 12, 215013272110132.	2.1	2
15	Managing Patients in the COVID-19 Pandemic. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 118-126.	2.4	20
16	Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research. <i>Mayo Clinic Proceedings</i> , 2021, 96, 601-618.	3.0	20
17	A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 868-873.	2.6	24
18	A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1250-1261.	3.0	45

#	ARTICLE	IF	CITATIONS
19	Preoperative Management of Surgical Patients Using Dietary Supplements. Mayo Clinic Proceedings, 2021, 96, 1342-1355.	3.0	5
20	The Association of Current Tobacco Status With Pain and Symptom Severity in Fibromyalgia Patients. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 614-624.	2.4	4
21	Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients. Open Forum Infectious Diseases, 2021, 8, ofab255.	0.9	56
22	Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. Journal of Infectious Diseases, 2021, 224, 1278-1286.	4.0	77
23	Perioperative Cardiac Risk Reduction in Noncardiac Surgery. Mayo Clinic Proceedings, 2021, 96, 2260-2276.	3.0	4
24	Reply to Puing et al. Journal of Infectious Diseases, 2021, , .	4.0	2
25	Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinicalMedicine, 2021, 40, 101102.	7.1	116
26	Implementation of a multisite, interdisciplinary remote patient monitoring program for ambulatory management of patients with COVID-19. Npj Digital Medicine, 2021, 4, 123.	10.9	42
27	Association of a Remote Patient Monitoring (RPM) Program With Reduced Hospitalizations in Cancer Patients With COVID-19. JCO Oncology Practice, 2021, 17, e1293-e1302.	2.9	18
28	Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. Journal of Clinical Investigation, 2021, 131, .	8.2	40
29	PROMIS Scales for Assessment of Persistent Post-COVID Symptoms: A Cross Sectional Study. Journal of Primary Care and Community Health, 2021, 12, 215013272110304.	2.1	21
30	Battlefield Acupuncture for Adult Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The American Journal of Chinese Medicine, 2021, 49, 25-40.	3.8	15
31	Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B.1.617.2 (Delta) surge. Journal of Clinical Virology, 2021, 145, 105026.	3.1	29
32	Biomarkers of thromboinflammation correlate to COVID-19 infection and admission status in emergency department patients. Thrombosis Update, 2021, 5, 100090.	0.9	2
33	Perioperative Venous Thromboembolism Prophylaxis. Mayo Clinic Proceedings, 2020, 95, 2775-2798.	3.0	46
34	Gut Health = Mental Health? The Impact of Diet and Dietary Supplements on Mood Disorders. Current Nutrition Reports, 2020, 9, 361-368.	4.3	9
35	Postural Tachycardia Syndrome: Nutrition Implications. Nutrition in Clinical Practice, 2020, 35, 818-825.	2.4	6
36	Telemedicine Consultations and Follow-up of Patients With COVID-19. Mayo Clinic Proceedings, 2020, 95, S33-S34.	3.0	31

#	ARTICLE	IF	CITATIONS
37	Perioperative Evaluation and Management of Endocrine Disorders. Mayo Clinic Proceedings, 2020, 95, 2760-2774.	3.0	22
38	Impact of herbs and dietary supplements in patients with fibromyalgia. Medicine (United States), 2020, 99, e20257.	1.0	1
39	A Process of Acceptance of Patient Photographs in Electronic Medical Records to Confirm Patient Identification. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 99-104.	2.4	2
40	The Stressed Executive: Sources and Predictors of Stress Among Participants in an Executive Health Program. Global Advances in Health and Medicine, 2018, 7, 216495611880615.	1.6	2
41	Casirivimab-Imdevimab Treatment Is Associated with Reduced Rates of Hospitalization Among High-Risk Patients with Mild to Moderate Coronavirus Disease-19. SSRN Electronic Journal, 0, , .	0.4	2
42	COVID-19: A 2020 update. Indian Journal of Medical Sciences, 0, 72, 88-94.	0.1	8
43	Dietary Supplements for Pain Relief in Patients with Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The American Journal of Chinese Medicine, 0, , 1-22.	3.8	0